These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 24730978)

  • 1. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.
    Brunzell DH; McIntosh JM; Papke RL
    Ann N Y Acad Sci; 2014 Oct; 1327(1):27-45. PubMed ID: 24730978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H; Hurst RS
    Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of AN6001, a positive allosteric modulator of α6β2-containing nicotinic acetylcholine receptors.
    van Hout M; Klein J; Ahring PK; Brown DT; Thaneshwaran S; Dos Santos AB; Jensen AA; Kohlmeier KA; Christophersen P; Dyhring T
    Biochem Pharmacol; 2020 Apr; 174():113788. PubMed ID: 31887290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotype.
    Brunzell DH
    Nicotine Tob Res; 2012 Nov; 14(11):1258-69. PubMed ID: 22492084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex.
    Livingstone PD; Srinivasan J; Kew JN; Dawson LA; Gotti C; Moretti M; Shoaib M; Wonnacott S
    Eur J Neurosci; 2009 Feb; 29(3):539-50. PubMed ID: 19187266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.
    Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A
    Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.
    Carroll FI; Navarro HA; Mascarella SW; Castro AH; Luetje CW; Wageman CR; Marks MJ; Jackson A; Damaj MI
    ACS Chem Neurosci; 2015 Jun; 6(6):920-6. PubMed ID: 25891987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotinic receptor antagonists as treatments for nicotine abuse.
    Crooks PA; Bardo MT; Dwoskin LP
    Adv Pharmacol; 2014; 69():513-51. PubMed ID: 24484986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable expression and functional characterization of a human nicotinic acetylcholine receptor with α6β2 properties: discovery of selective antagonists.
    Capelli AM; Castelletti L; Chen YH; Van der Keyl H; Pucci L; Oliosi B; Salvagno C; Bertani B; Gotti C; Powell A; Mugnaini M
    Br J Pharmacol; 2011 May; 163(2):313-29. PubMed ID: 21232042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.
    Quik M; Campos C; Grady SR
    Biochem Pharmacol; 2013 Oct; 86(8):1153-62. PubMed ID: 23831952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
    Bordia T; Hrachova M; Chin M; McIntosh JM; Quik M
    J Pharmacol Exp Ther; 2012 Aug; 342(2):327-34. PubMed ID: 22550286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization.
    Moretti M; Zoli M; George AA; Lukas RJ; Pistillo F; Maskos U; Whiteaker P; Gotti C
    Mol Pharmacol; 2014 Sep; 86(3):306-17. PubMed ID: 25002271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heteromeric α7β2 Nicotinic Acetylcholine Receptors in the Brain.
    Wu J; Liu Q; Tang P; Mikkelsen JD; Shen J; Whiteaker P; Yakel JL
    Trends Pharmacol Sci; 2016 Jul; 37(7):562-574. PubMed ID: 27179601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia.
    Ishikawa M; Hashimoto K
    Curr Pharm Des; 2011; 17(2):121-9. PubMed ID: 21355839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
    Sala M; Braida D; Pucci L; Manfredi I; Marks MJ; Wageman CR; Grady SR; Loi B; Fucile S; Fasoli F; Zoli M; Tasso B; Sparatore F; Clementi F; Gotti C
    Br J Pharmacol; 2013 Feb; 168(4):835-49. PubMed ID: 22957729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α7 and β2 Nicotinic Acetylcholine Receptor Subunits Form Heteromeric Receptor Complexes that Are Expressed in the Human Cortex and Display Distinct Pharmacological Properties.
    Thomsen MS; Zwart R; Ursu D; Jensen MM; Pinborg LH; Gilmour G; Wu J; Sher E; Mikkelsen JD
    PLoS One; 2015; 10(6):e0130572. PubMed ID: 26086615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
    Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
    J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors.
    Yohn NL; Turner JR; Blendy JA
    J Pharmacol Exp Ther; 2014 May; 349(2):348-54. PubMed ID: 24627467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators.
    Wilkerson JL; Deba F; Crowley ML; Hamouda AK; McMahon LR
    Neuropharmacology; 2020 May; 168():108008. PubMed ID: 32113032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
    Faghih R; Gfesser GA; Gopalakrishnan M
    Recent Pat CNS Drug Discov; 2007 Jun; 2(2):99-106. PubMed ID: 18221220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.